Vietnamese herbal medicine (TD0019) in the treatment of cervical radiculopathy: A double-blind phase-2 randomized controlled trial

被引:1
作者
Ha, Nguyen Thi Thu [1 ]
Vuong, Nguyen Lam [2 ]
Lua, Trinh Thi [1 ]
Nguyen, Trang Thi Minh [2 ]
Nghia, Duong Trong [3 ]
Nga, Ha Thi Viet [3 ]
Anh, Pham Thi Van [4 ]
Truc, Thai Thanh [2 ]
Dung, Do Van [2 ]
机构
[1] Hanoi Med Univ, Fac Tradit Med, Hanoi, Vietnam
[2] Univ Med & Pharm Ho Chi Minh City, Fac Publ Hlth, Dept Med Stat & Informat, 217 Hong Bang St,Ward 11,Dist 5, Ho Chi Minh City, Vietnam
[3] Natl Hosp Tradit Med, Hanoi, Vietnam
[4] Hanoi Med Univ, Dept Pharmacol, Hanoi, Vietnam
关键词
Cervical radiculopathy; Intervertebral disc degeneration; Neck disability index; Vietnamese herbal medicine formula; TD0019; Randomized controlled trial; NECK PAIN; EPIDEMIOLOGY;
D O I
10.1016/j.eujim.2020.101060
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Introduction: Cervical radiculopathy causes chronic pain and reduces patients' quality of life. Oral analgesics are commonly used but only after careful consideration due to their complications. TD0019, a Vietnamese herbal medicine, composed of Duhuo Jisheng decoction, nattokinase and an extract of Salix alba cortex has shown evidence of some benefits for these patients in pre-clinical and phase-1 studies. This study aimed to evaluate the efficacy and safety of TD0019 in the treatment of cervical radiculopathy. Methods: In this double-blind phase-2 trial, 180 patients with symptomatic cervical radiculopathy were randomized to either group 1 with intended dose of TD0019, group 2 with a higher dose (1.5 times the intended dose), or group 3, a placebo. The primary efficacy endpoint was the neck-specific disability score according to the Neck Disability Index (NDI) questionnaire. The safety endpoint included adverse events (AEs) and serious adverse events (SAEs). All patients received the drugs for 30 days and were followed for 60 days. Results: Baseline characteristics were similar for the three groups. The reduction of NDI score from baseline to the end of study was greatest for group 2 (from 17.6 +/- 7.2 to 4.8 +/- 5.1), followed by group 1 (from 16.1 +/- 6.9 to 5.4 +/- 5.1) and placebo group (from 15.6 +/- 6.2 to 7.8 +/- 6.8), with a significant decrease for both groups compared to placebo. The percentage of AEs was comparable among three groups and no SAEs occurred. Conclusions: TD0019 was superior to placebo for the reduction of symptoms with similar rates of side effects. The higher dose is more beneficial than the intended dose. This herbal medicine may be a potential alternative analgesic in the treatment of cervical radiculopathy.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Radiofrequency treatment relieves chronic knee osteoarthritis pain: A double-blind randomized controlled trial
    Choi, Woo-Jong
    Hwang, Seung-Jun
    Song, Jun-Gol
    Leem, Jeong-Gil
    Kang, Yong-Up
    Park, Pyong-Hwan
    Shin, Jin-Woo
    PAIN, 2011, 152 (03) : 481 - 487
  • [32] Trimethoprim as Adjuvant Treatment in Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial
    Shibre, Teshome
    Alem, Atalay
    Abdulahi, Abdulreshid
    Araya, Mesfin
    Beyero, Teferra
    Medhin, Girmay
    Deyassa, Negusse
    Negash, Alemayehu
    Nigatu, Alemayehu
    Kebede, Derege
    Fekadu, Abebaw
    SCHIZOPHRENIA BULLETIN, 2010, 36 (04) : 846 - 851
  • [33] Psychological Treatment of Comorbid Insomnia and Depression: A Double-Blind Randomized Placebo-Controlled Trial
    Blom, Kerstin
    Forsell, Erik
    Hellberg, Monica
    Svanborg, Cecilia
    Jernelov, Susanna
    Kaldo, Viktor
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2024, 93 (02) : 100 - 113
  • [34] Chinese herbal medicine formula for acute asthma: A multi-center, randomized, double-blind, proof-of-concept trial
    Zhang, Hong Ping
    Wang, Lei
    Wang, Zhen
    Xu, Xian Rong
    Zhou, Xian Mei
    Liu, Gang
    He, Lv Yuan
    Wang, Jun
    Hsu, Alan
    Li, Wei Min
    Wang, Gang
    RESPIRATORY MEDICINE, 2018, 140 : 42 - 49
  • [35] Efficacy and Safety of Chinese Herbal Medicine Compared With Losartan for Mild Essential Hypertension: A Randomized, Multicenter, Double-Blind, Noninferiority Trial
    Lai, Xinxing
    Dong, Zhenyu
    Wu, Shengxian
    Zhou, Xiaohua
    Zhang, Genming
    Xiong, Shangquan
    Wu, Wei
    Cao, Rui
    Wang, Xiaolong
    Hua, Qi
    Du, Jinhang
    Fan, Jinying
    Mao, Jingyuan
    Jiang, Weimin
    Yuan, Huishu
    Chen, Yushan
    Xu, Yong
    Li, Zhanquan
    Zhang, Jun
    Dong, Guiying
    Zhen, Hui
    Ding, Ru
    Wu, Zonggui
    Gao, Ying
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2022, 15 (03): : E007923
  • [36] Oral Chinese Herbal Medicine plus usual care for diabetic kidney disease: study protocol for a randomized, double-blind, placebo-controlled pilot trial
    Liu, Meifang
    Di, Yuan Ming
    Zhang, Lei
    Yang, Lihong
    Zhang, La
    Chen, Junhui
    Wang, Ruobing
    Xie, Xiaoning
    Lan, Fang
    Xie, Liping
    Huang, Juan
    Zhang, Anthony Lin
    Xue, Charlie Changli
    Liu, Xusheng
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [37] Individualized Homeopathic Medicines in the Treatment of Tinea Corporis: Double-Blind, Randomized, Placebo-Controlled Trial
    Laskar, Bakibillah
    Paul, Swapan
    Chattopadhyay, Abhijit
    Karuppusamy, Avaranjika
    Balamurugan, Dharshna
    Bhakta, Puja
    Das, Sourav
    Pal, Siddhartha
    Singh, Navin Kumar
    Koley, Munmun
    Saha, Subhranil
    HOMEOPATHY, 2023, 112 (02) : 74 - 84
  • [38] Ifenprodil for the treatment of methamphetamine use disorder: An exploratory, randomized, double-blind, placebo-controlled trial
    Kotajima-Murakami, Hiroko
    Takano, Ayumi
    Hirakawa, Shinya
    Ogai, Yasukazu
    Funada, Daisuke
    Tanibuchi, Yuko
    Ban, Eriko
    Kikuchi, Minako
    Tachimori, Hisateru
    Maruo, Kazushi
    Kawashima, Takahiro
    Tomo, Yui
    Sasaki, Tsuyoshi
    Oi, Hideki
    Matsumoto, Toshihiko
    Ikeda, Kazutaka
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2022, 42 (01) : 92 - 104
  • [39] Can moxibustion, an ancient treatment modality, be evaluated in a double-blind randomized controlled trial? —— A narrative review
    Bai-xiao Zhao
    Hai-Yong Chen
    Xue-yong Shen
    Lixing Lao
    Journal of Integrative Medicine, 2014, (03) : 131 - 134
  • [40] Individualized Homeopathic Medicines in Treatment of Vitiligo: Double-Blind, Randomized, Placebo-Controlled Pilot Trial
    Karuppusamy, Avaranjika
    Paul, Swapan
    Chattopadhyay, Abhijit
    Balamurugan, Dharshna
    Malathi, Maria
    Kumar, Ashwani
    Suchiang, Eiphrangdaka Lyngdoh
    Sadhukhan, Satarupa
    Koley, Munmun
    Saha, Subhranil
    JOURNAL OF INTEGRATIVE AND COMPLEMENTARY MEDICINE, 2022, 28 (01): : 96 - 102